Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
- Авторлар: Zanghì A.1, Ferraro D.2, Callari G.3, Valentino P.4, Granella F.5, Patti F.6, Lus G.7, Bonavita S.8, Moretti M.1, Avolio C.1, DAmico E.9
-
Мекемелер:
- Department of Medical and Surgical Sciences, University of Foggia
- , University of Modena and Reggio Emilia
- , IRCSS G.Giglio
- , Azienda Ospedaliera Universitaria "Mater Domini"
- Unit of Neurosciences, Department of Medicine and Surgery, University of Parma
- Department "G.F. Ingrassia, MS center University of Catania
- Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine,, Second University of Naples
- Dipartimento di Scienze Mediche e Chirurgiche Avanzate, Università della Campania Luigi Vanvitelli,
- Department of Medical and Surgical Sciences,, University of Foggia,
- Шығарылым: Том 22, № 2 (2024)
- Беттер: 339-345
- Бөлім: Neurology
- URL: https://rjpbr.com/1570-159X/article/view/644655
- DOI: https://doi.org/10.2174/1570159X22666231002142709
- ID: 644655
Дәйексөз келтіру
Толық мәтін
Аннотация
Background:The intervals between two courses of anti CD20 therapies in the COVID19 pandemic era provided the opportunity to individually delay therapy, known as extended interval dosing (EID).
Materials and Methods:We collect real-world data on patients with primary progressive MS (PPMS) treated with Ocrelizumab (OCR) during the COVID19 pandemic. The observation period in which the standard interval dosing (SID) or EID occurred (always a maintenance cycle, 600 mg) was from January 2020 to June 2021. All patients had two infusions during the observation period. Our first aim was to compare confirmed disability progression (CDP) between SID and EID patients.
Results:From a total cohort of 410 patients treated with OCR, 96 patients fulfilled the inclusion criteria. All patients received two infusions during the index window, 71 received only SID infusions whilst 25 received at least one EID infusion throughout the entire follow-up. During the entire available follow-up (median 10 months, IQR 7-11), CDP was recorded in 5 patients (3/71, 4.2% SID and 2/25, 8% EID, V-Cramer = 0.141, p-value = 0.167). EID regimen did not influence the risk of CDP during the investigated follow up.
Conclusion:In our multicentre real-world cohort, the EID regimen in PPMS patients did not result in increased CDP during the available follow-up.
Авторлар туралы
Aurora Zanghì
Department of Medical and Surgical Sciences, University of Foggia
Email: info@benthamscience.net
Diana Ferraro
, University of Modena and Reggio Emilia
Email: info@benthamscience.net
Graziella Callari
, IRCSS G.Giglio
Email: info@benthamscience.net
Paola Valentino
, Azienda Ospedaliera Universitaria "Mater Domini"
Email: info@benthamscience.net
Franco Granella
Unit of Neurosciences, Department of Medicine and Surgery, University of Parma
Email: info@benthamscience.net
Francesco Patti
Department "G.F. Ingrassia, MS center University of Catania
Email: info@benthamscience.net
Giacomo Lus
Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine,, Second University of Naples
Email: info@benthamscience.net
Simona Bonavita
Dipartimento di Scienze Mediche e Chirurgiche Avanzate, Università della Campania Luigi Vanvitelli,
Email: info@benthamscience.net
Maria Moretti
Department of Medical and Surgical Sciences, University of Foggia
Email: info@benthamscience.net
Carlo Avolio
Department of Medical and Surgical Sciences, University of Foggia
Email: info@benthamscience.net
Emanuele DAmico
Department of Medical and Surgical Sciences,, University of Foggia,
Хат алмасуға жауапты Автор.
Email: info@benthamscience.net
Әдебиет тізімі
- Rolfes, L.; Pawlitzki, M.; Pfeuffer, S.; Nelke, C.; Lux, A.; Pul, R. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol. Neuroimmunol. Neuroinflamm., 2021, 8(5), e1035. doi: 10.1212/NXI.0000000000001035 PMID: 34261812
- Bar-Or, A.; Calabresi, P.A.J.; Arnold, D.; Markowitz, C.; Shafer, S.; Kasper, L.H.; Waubant, E.; Gazda, S.; Fox, R.J.; Panzara, M.; Sarkar, N.; Agarwal, S.; Smith, C.H. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann. Neurol., 2008, 63(3), 395-400. doi: 10.1002/ana.21363 PMID: 18383069
- DAmico, E.; Zanghì, A.; Chisari, C.G.; Fermo, S.L.; Toscano, S.; Arena, S.; Patti, F.; Zappia, M. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Mult. Scler. Relat. Disord., 2019, 27, 324-326. doi: 10.1016/j.msard.2018.09.041 PMID: 30471585
- Furlan, A.; Forner, G.; Cipriani, L.; Vian, E.; Rigoli, R.; Gherlinzoni, F.; Scotton, P. COVID-19 in B cell-depleted patients after rituximab: A diagnostic and therapeutic challenge. Front. Immunol., 2021, 12, 763412. doi: 10.3389/fimmu.2021.763412 PMID: 34804051
- DAmico, E.; Zanghì, A.; Gastaldi, M.; Patti, F.; Zappia, M.; Franciotta, D. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun. Rev., 2019, 18(7), 665-672. doi: 10.1016/j.autrev.2019.05.003 PMID: 31059839
- Schiavetti, I.; Ponzano, M.; Signori, A.; Bovis, F.; Carmisciano, L.; Sormani, M.P. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Mult. Scler. Relat. Disord., 2022, 57, 103358. doi: 10.1016/j.msard.2021.103358 PMID: 35158467
- Simpson-Yap, S.; De Brouwer, E.; Kalincik, T.; Rijke, N.; Hillert, J.A.; Walton, C.; Edan, G.; Moreau, Y.; Spelman, T.; Geys, L.; Parciak, T.; Gautrais, C.; Lazovski, N.; Pirmani, A.; Ardeshirdavanai, A.; Forsberg, L.; Glaser, A.; McBurney, R.; Schmidt, H.; Bergmann, A.B.; Braune, S.; Stahmann, A.; Middleton, R.; Salter, A.; Fox, R.J.; van der Walt, A.; Butzkueven, H.; Alroughani, R.; Ozakbas, S.; Rojas, J.I.; van der Mei, I.; Nag, N.; Ivanov, R.; Sciascia do Olival, G.; Dias, A.E.; Magyari, M.; Brum, D.; Mendes, M.F.; Alonso, R.N.; Nicholas, R.S.; Bauer, J.; Chertcoff, A.S.; Zabalza, A.; Arrambide, G.; Fidao, A.; Comi, G.; Peeters, L. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology, 2021, 97(19), e1870-e1885. doi: 10.1212/WNL.0000000000012753 PMID: 34610987
- Sormani, M.P.; De Rossi, N.; Schiavetti, I.; Carmisciano, L.; Cordioli, C.; Moiola, L.; Radaelli, M.; Immovilli, P.; Capobianco, M.; Trojano, M.; Zaratin, P.; Tedeschi, G.; Comi, G.; Battaglia, M.A.; Patti, F.; Salvetti, M.; Nozzolillo, A.; Bellacosa, A.; Protti, A.; Di Sapio, A.; Signori, A.; Petrone, A.; Bisecco, A.; Iovino, A.; Dutto, A.; Repice, A.M.; Conte, A.; Bertolotto, A.; Bosco, A.; Gallo, A.; Zito, A.; Sartori, A.; Giometto, B.; Tortorella, C.; Antozzi, C.; Pozzilli, C.; Mancinelli, C.R.; Zanetta, C.; Cordano, C.; Cordioli, C.; Scandellari, C.; Guaschino, C.; Gasperini, C.; Solaro, C.; Fioretti, C.; Bezzini, D.; Marastoni, D.; Paolicelli, D.; Vecchio, D.; Landi, D.; Bucciantini, E.; Pedrazzoli, E.; Signoriello, E.; Sbragia, E.; Susani, E.L.; Curti, E.; Milano, E.; Marinelli, F.; Camilli, F.; Boneschi, F.M.; Govone, F.; Bovis, F.; Calabria, F.; Caleri, F.; Rinaldi, F.; Vitetta, F.; Corea, F.; Crescenzo, F.; Patti, F.; Teatini, F.; Tabiadon, G.; Granella, F.; Boffa, G.; Lus, G.; Brichetto, G.; Comi, G.; Tedeschi, G.; Maniscalco, G.T.; Borriello, G.; De Luca, G.; Konrad, G.; Vaula, G.; Marfia, G.A.; Mallucci, G.; Liberatore, G.; Salemi, G.; Miele, G.; Sibilia, G.; Pesci, I.; Schiavetti, I.; Brambilla, L.; Lopiano, L.; Sinisi, L.; Pasquali, L.; Saraceno, L.; Carmisciano, L.; Chiveri, L.; Mancinelli, L.; Moiola, L.; Grimaldi, L.M.E.; Caniatti, L.M.; Capobianco, M.; Cava, M.D.; Onofrj, M.; Rovaris, M.; Salvetti, M.; Vercellino, M.; Bragadin, M.M.; Buccafusca, M.; Buscarinu, M.C.; Celani, M.G.; Grasso, M.G.; Stromillo, M.L.; Petracca, M.; Amato, M.P.; Sormani, M.P.; LEpiscopo, M.R.; Sessa, M.; Ferrò, M.T.; Trojano, M.; Ercolani, M.V.; Bianco, M.; Re, M.L.; Vianello, M.; Clerico, M.; Battaglia, M.A.; Napoli, M.; Ponzano, M.; Radaelli, M.; Conti, M.Z.; Calabrese, M.; Mirabella, M.; Filippi, M.; Inglese, M.; Lucchini, M.; Pozzato, M.; Danni, M.C.; Zaffaroni, M.; Zampolini, M.; Ponzio, M.; De Riz, M.; De Rossi, N.; De Stefano, N.; Cavalla, P.; De Mitri, P.; Grossi, P.; Zaratin, P.; Confalonieri, P.; Gallo, P.; Immovilli, P.; Ragonese, P.; Sola, P.; Annovazzi, P.; Iaffaldano, P.; Nardone, R.; Cerqua, R.; Clerici, R.; Lanzillo, R.; Motta, R.; Balgera, R.; Bergamaschi, R.; Totaro, R.; Iodice, R.; Capra, R.; Marangoni, S.; Realmuto, S.; Cottone, S.; Montepietra, S.; Rasia, S.; Arena, S.; Bucello, S.; Banfi, S.; Bonavita, S.; Malucchi, S.; Tonietti, S.; Vollaro, S.; Cordera, S.; Aguglia, U.; Clerici, V.T.; Barcella, V.; Bergamaschi, V.; Morra, V.B.; Dattola, V.; Mantero, V. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann. Neurol., 2021, 89(4), 780-789. doi: 10.1002/ana.26028 PMID: 33480077
- Giovannoni, G. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult. Scler. Relat. Disord., 2020, 41, 102135. doi: 10.1016/j.msard.2020.102135 PMID: 32339915
- Hada, M.; Mosholder, A.D.; Leishear, K.; Perez-Vilar, S. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol. Sci., 2022, 43(3), 1557-1567. doi: 10.1007/s10072-021-05846-3 PMID: 35006442
- Sharifian-Dorche, M.; Sahraian, M.A.; Fadda, G.; Osherov, M.; Sharifian-Dorche, A.; Karaminia, M.; Saveriano, A.W.; La Piana, R.; Antel, J.P.; Giacomini, P.S. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult. Scler. Relat. Disord., 2021, 50, 102800. doi: 10.1016/j.msard.2021.102800 PMID: 33578206
- Baba, C.; Yigit, P.; Dastan, S.; Hancer, P.; Sagici, O.; Ozakbas, S.; Abasiyanik, Z. Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic. Neurol. Clin. Neurosci., 2022, 10(1), 3-8. doi: 10.1111/ncn3.12561 PMID: 34909197
- Silveira, C.; Guedes, R.; Maia, D.; Curral, R.; Coelho, R. Neuropsychiatric symptoms of multiple sclerosis: State of the art. Psychiatry Investig., 2019, 16(12), 877-888. doi: 10.30773/pi.2019.0106 PMID: 31805761
- Available from:https://www.aifa.gov.it/sites/default/files/Ocrevus.pdf
- Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; Fujihara, K.; Galetta, S.L.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Marrie, R.A.; Miller, A.E.; Miller, D.H.; Montalban, X.; Mowry, E.M.; Sorensen, P.S.; Tintoré, M.; Traboulsee, A.L.; Trojano, M.; Uitdehaag, B.M.J.; Vukusic, S.; Waubant, E.; Weinshenker, B.G.; Reingold, S.C.; Cohen, J.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol., 2018, 17(2), 162-173. doi: 10.1016/S1474-4422(17)30470-2 PMID: 29275977
- Available from:https://www.neurostatus.net/
- Available from:https://www.salute.gov.it/portale/nuovocorona-virus/dettaglioFaqNuovoCoronavirus.jsp?lingua=english&id=230
- Sahi, N.K.; Abidi, S.M.A.; Salim, O.; Abraham, R.; Kalra, S.; Al-Araji, A. Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation. Mult. Scler. Relat. Disord., 2021, 56, 103287. doi: 10.1016/j.msard.2021.103287 PMID: 34627005
- van Lierop, Z.Y.G.J.; Toorop, A.A.; van Ballegoij, W.J.C.; Olde Dubbelink, T.B.G.; Strijbis, E.M.M.; de Jong, B.A.; van Oosten, B.W.; Moraal, B.; Teunissen, C.E.; Uitdehaag, B.M.J.; Killestein, J.; Kempen, Z.L.E. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult. Scler., 2022, 28(7), 1121-1125. doi: 10.1177/13524585211028833 PMID: 34240631
- Zanghì, A.; Avolio, C.; Signoriello, E.; Abbadessa, G.; Cellerino, M.; Ferraro, D.; Messina, C.; Barone, S.; Callari, G.; Tsantes, E.; Sola, P.; Valentino, P.; Granella, F.; Patti, F.; Lus, G.; Bonavita, S.; Inglese, M.; DAmico, E. Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? evidence from an italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics, 2022, 19(5), 1535-1545. doi: 10.1007/s13311-022-01289-6 PMID: 36036858
- Montalban, X.; Hauser, S.L.; Kappos, L.; Arnold, D.L.; Bar-Or, A.; Comi, G.; de Seze, J.; Giovannoni, G.; Hartung, H.P.; Hemmer, B.; Lublin, F.; Rammohan, K.W.; Selmaj, K.; Traboulsee, A.; Sauter, A.; Masterman, D.; Fontoura, P.; Belachew, S.; Garren, H.; Mairon, N.; Chin, P.; Wolinsky, J.S. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med., 2017, 376(3), 209-220. doi: 10.1056/NEJMoa1606468 PMID: 28002688
- DAmico, E.; Patti, F.; Zanghì, A.; Zappia, M. A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int. J. Mol. Sci., 2016, 17(10), 1725. doi: 10.3390/ijms17101725 PMID: 27763513
- Zanghì, A.; DAmico, E.; Luca, M.; Ciaorella, M.; Basile, L.; Patti, F. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Mult. Scler. Relat. Disord., 2020, 46, 102561. doi: 10.1016/j.msard.2020.102561 PMID: 33045494
- van Kempen, Z.L.E.; Hoogervorst, E.L.J.; Wattjes, M.P.; Kalkers, N.F.; Mostert, J.P.; Lissenberg-Witte, B.I. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology, 2020, 95(6), e745-e754. doi: 10.1212/WNL.0000000000009995 PMID: 32690785
- Ellrichmann, G.; Bolz, J.; Peschke, M.; Duscha, A.; Hellwig, K.; Lee, D.H.; Linker, R.A.; Gold, R.; Haghikia, A. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J. Neurol., 2019, 266(1), 57-67. doi: 10.1007/s00415-018-9092-4 PMID: 30377816
- Benkert, P.; Meier, S.; Schaedelin, S.; Manouchehrinia, A.; Yaldizli, Ö.; Maceski, A.; Oechtering, J.; Achtnichts, L.; Conen, D.; Derfuss, T.; Lalive, P.H.; Mueller, C.; Müller, S.; Naegelin, Y.; Oksenberg, J.R.; Pot, C.; Salmen, A.; Willemse, E.; Kockum, I.; Blennow, K.; Zetterberg, H.; Gobbi, C.; Kappos, L.; Wiendl, H.; Berger, K.; Sormani, M.P.; Granziera, C.; Piehl, F.; Leppert, D.; Kuhle, J.; Aeschbacher, S.; Barakovic, M.; Buser, A.; Chan, A.; Disanto, G.; DSouza, M.; Du Pasquier, R.; Findling, O.; Galbusera, R.; Hrusovsky, K.; Khalil, M.; Lorscheider, J.; Mathias, A.; Orleth, A.; Radue, E-W.; Rahmanzadeh, R.; Sinnecker, T.; Subramaniam, S.; Vehoff, J.; Wellmann, S.; Wuerfel, J.; Zecca, C. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol., 2022, 21(3), 246-257. doi: 10.1016/S1474-4422(22)00009-6 PMID: 35182510
Қосымша файлдар
